Aureus Pharma Licenses AurWEB to Origenis

Thursday, September 07, 2006 Print


Aureus Pharma has announced that Origenis has become the first customer subscribing to its AurWEB portal.

AurWEB is designed to allow researchers to gain access to all of Aureus’ knowledge databases, which include AurSCOPE GPCR, Ion Channel, Kinase, ADME/Drug-Drug interactions and hERG as well as the accompanying applications.

All are available via a secure web portal on a subscription basis. Origenis employs up-to-date knowledge bases to incorporate relevant biological and pharmacological data into the drug design process.

Origenis uses proprietary methods to generate predictive QSAR and QSPR models for its design, and creates pre-clinical compounds target and indication optimised using a direct multi-objective approach.

"With AurWEB the data integration into MOREsystem® was straightforward," said Dr. Michael Thormann, Managing Director of Origenis GmbH.

"AurWeb represents a valuable, exemplary data source. We use AurWeb to turn highly relevant knowledge into powerful models for our technology platform."

"This accelerates our drug discovery projects and improves the quality of the resulting compounds."

"We are pleased to have Origenis join our growing list of customers," said Dr. Andre Michel of Aureus Pharma.

"AurWEB with its flexible access to biological and chemical activity data for important drug target families will complement Origenis approach to discover novel target focussed drug candidates."